Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Lee

Interventional Cardiology Brooklyn, NY Medical Doctor

NPI 1518919182 CMS profile 23830

833 58Th St, Brooklyn, NY 11220

Open in the dashboard

General payments

$12,251

444 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Lee of Brooklyn, NY is reported in the CMS Open Payments database as having received $12,251 across 444 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,397 69
2024 General $2,025 67
2023 General $1,653 61
2022 General $1,367 51
2021 General $652 18
2020 General $929 50
2019 General $3,228 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Lee
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Paul Lee were reported at $2,397. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Paul Lee Interventional Cardiology median Middle half National median
2019 $3,228 $1,097 $329–$3,048 $163
2020 $929 $473 $161–$1,480 $114
2021 $652 $677 $233–$1,827 $132
2022 $1,367 $978 $333–$2,724 $149
2023 $1,653 $1,136 $382–$2,986 $160
2024 $2,025 $1,181 $395–$3,326 $164
2025 $2,397 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,789 51 payments
  2. Abbott Laboratories $1,515 13 payments
  3. AstraZeneca Pharmaceuticals LP $1,418 55 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $924 45 payments
  5. Amgen Inc. $916 37 payments
  6. Novartis Pharmaceuticals Corporation $692 35 payments
  7. E.R. Squibb & Sons, L.L.C. $577 29 payments
  8. Merck Sharp & Dohme Corporation $551 25 payments
  9. Pfizer Inc. $544 25 payments
  10. Abiomed $516 6 payments
  11. Other $2,809 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,124 430 payments
  2. Education $127 14 payments
Products named General payments · program years 2019–2025
  1. Kerendia $1,789 51 payments
  2. JARDIANCE $816 40 payments
  3. VERQUVO $664 29 payments
  4. Repatha $635 32 payments
  5. FARXIGA $543 19 payments
  6. LEQVIO $449 21 payments
  7. ELIQUIS Cardiovascular $436 22 payments
  8. ELIQUIS Cardiovascular;Metabolic Disease $432 19 payments
  9. CardioMEMS HF System $378 3 payments
  10. BRILINTA $343 18 payments
  11. Other $6,764 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

15,875

Median for Cardiology: 2,533

Drug cost

$4,522,826

Median for Cardiology: $485,213

Branded share of claims

42.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,579 $1,115,275
Camzyos Mavacamten Brand 55 $453,866
Jardiance Empagliflozin Brand 616 $444,374
Entresto Sacubitril/Valsartan Brand 606 $433,095
Kerendia Finerenone Brand 423 $291,340
Farxiga Dapagliflozin Propanediol Brand 431 $287,927
Vyndamax Tafamidis Brand 12 $249,577
Multaq Dronedarone Hcl Brand 252 $201,711
Rybelsus Semaglutide Brand 195 $195,482
Diclofenac Epolamine Generic 126 $105,879

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$99,281

Of which drugs: $1,151

Medicare patients

201

Average age 81

Services billed

1,512

109 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Chronic kidney disease 54%
Diabetes 50%
Arthritis 48%
Heart failure 37%
Atrial fibrillation 36%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 43 172 $1,106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $332
$332 423 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $248
$248 431 —
VERQUVO
  • Merck Sharp & Dohme Corporation $180
$180 73 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $95
  • PFIZER INC. $68
$163 1,579 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

444 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record